IHC
Ventana Medical Systems Inc., part of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum) and University Hospital Heidelberg, Germany, to commercialize a novel immunohistochemistry (IHC) primary antibody. Designed to detect the V600E BRAF mutation protein, the new IHC diagnostic from Ventana will add to Roche's portfolio of BRAF diagnostics. The BRAF protein plays a role in regulating cell signaling, and it has...